Cell Therapeutics (CTIC) Submits Ppixantrone NDA to FDA, Requests Priority Review
More News related to CTIC
- Unusual 11 Mid-Day Movers 2/9: ACLI, CLWT, CTIC, NBG, ECPG Higher; TRID, MGAM, CONN, TMRK Lower
- Morning Movers 2/9: ACLI, CTIC, HAR, ADCT, COIN Higher; TRGL, CONN, TRID, TMRK Lower
- Cell Therapeutics (CTIC) Pixantrone NDA Meeting Delayed by U.S. FDA Due to Inclement Waether
- FDA Postpones Oncologic Drugs Advisory Committee Meeting to Review Pixantrone Due to Severe Weather Conditions
- Unusual 11 Mid-Day Movers 2/8: IIG, CFSG, PNX, HAS Higher; CTIC, SHIP, NVAX, NBG Lower
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Cell Therapeutics, Inc. (Nasdaq: CTIC) has completed the submission of the New Drug Application (NDA) to the FDA for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).
CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.
Related Categories
FDAStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
